Baseline multi‐omics signatures could predict therapeutic response to neoadjuvant anti‐PD‐1 immunochemotherapy in non‐small‐cell lung cancer

Abstract Background Neoadjuvant anti‐programmed cell death 1 (PD‐1) immunochemotherapy has shown promising efficiency in the treatment of early‐stage non‐small‐cell lung cancer (NSCLC), but it has not consistently yielded durable responses. Biomarkers for the prediction of efficacy are warranted. Me...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ailing Cao, Yaobin Lin, Shaoxing Guan, Youhao Chen, Wenyu Zhai, Yuheng Zhou, Shoucheng Feng, Yanping Guan, Yiyu Zhang, Min Huang, Xueding Wang, Hao Long
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2026-01-01
Col·lecció:	Clinical and Translational Medicine
Matèries:	gut microbiota metabolomics neoadjuvant NSCLC PD‐1
Accés en línia:	https://doi.org/10.1002/ctm2.70579
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!